Literature DB >> 19912265

SMARCB1/INI1 maternal germ line mosaicism in schwannomatosis.

T J M Hulsebos1, S B Kenter, M E Jakobs, F Baas, B Chong, M B Delatycki.   

Abstract

Schwannomatosis is characterized by the development of multiple schwannomas of the nervous system, but without the occurrence of vestibular schwannomas. Most cases of schwannomatosis are thought to be sporadic, representing the first case in a family due to a new mutation in the causative gene. We recently identified SMARCB1/INI1 as a schwannomatosis-predisposing gene. Here, we analyzed this gene in a schwannomatosis family with two affected children, but with clinically unaffected parents. Both affected individuals carried a constitutional SMARCB1 mutation, c.1118+ 1G>A, that changes the donor splice site sequence of intron 8, causing skipping of exon 8 and resulting in the in-frame deletion of 132 nucleotides in the transcript. The mutation was not evident in constitutional DNA of the parents. Haplotyping revealed that the chromosome 22 segment that carries the mutant SMARCB1 allele originated from the mother. She transferred the same chromosome 22 segment, however, with a wild-type SMARCB1 copy, to a third unaffected child. Our findings indicate that the mother is germ line mosaic for the SMARCB1 mutation. In conclusion, our study shows for the first time that germ line mosaicism may occur in schwannomatosis, which has implications for genetic counseling in this disease.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19912265     DOI: 10.1111/j.1399-0004.2009.01249.x

Source DB:  PubMed          Journal:  Clin Genet        ISSN: 0009-9163            Impact factor:   4.438


  8 in total

1.  Epithelioid malignant peripheral nerve sheath tumor arising in a schwannoma, in a patient with "neuroblastoma-like" schwannomatosis and a novel germline SMARCB1 mutation.

Authors:  Jodi M Carter; Carolyn O'Hara; George Dundas; Dawna Gilchrist; Mark S Collins; Katherine Eaton; Alexander R Judkins; Jaclyn A Biegel; Andrew L Folpe
Journal:  Am J Surg Pathol       Date:  2012-01       Impact factor: 6.394

2.  Update from the 2011 International Schwannomatosis Workshop: From genetics to diagnostic criteria.

Authors:  Scott R Plotkin; Jaishri O Blakeley; D Gareth Evans; C Oliver Hanemann; Theo J M Hulsebos; Kim Hunter-Schaedle; Ganjam V Kalpana; Bruce Korf; Ludwine Messiaen; Laura Papi; Nancy Ratner; Larry S Sherman; Miriam J Smith; Anat O Stemmer-Rachamimov; Jeremie Vitte; Marco Giovannini
Journal:  Am J Med Genet A       Date:  2013-02-07       Impact factor: 2.802

3.  SMARCB1/INI1 germline mutations contribute to 10% of sporadic schwannomatosis.

Authors:  Guillaume Rousseau; Tetsuro Noguchi; Violaine Bourdon; Hagay Sobol; Sylviane Olschwang
Journal:  BMC Neurol       Date:  2011-01-24       Impact factor: 2.474

4.  Spectrum of SMARCB1/INI1 mutations in familial and sporadic rhabdoid tumors.

Authors:  Katherine W Eaton; Laura S Tooke; Luanne M Wainwright; Alexander R Judkins; Jaclyn A Biegel
Journal:  Pediatr Blood Cancer       Date:  2011-01       Impact factor: 3.167

5.  Clinical characteristics and genetic testing outcome of suspected hereditary peripheral nerve sheath tumours in a tertiary cancer institution in Singapore.

Authors:  Jerold Loh; Pei Yi Ong; Denise Li Meng Goh; Mark E Puhaindran; Balamurugan A Vellayappan; Samuel Guan Wei Ow; Gloria Chan; Soo-Chin Lee
Journal:  Hered Cancer Clin Pract       Date:  2022-06-13       Impact factor: 2.164

6.  Genetics of Bladder Malignant Tumors in Childhood.

Authors:  Andrea Zangari; Johan Zaini; Caterina Gulìa
Journal:  Curr Genomics       Date:  2016-02       Impact factor: 2.236

Review 7.  The molecular pathogenesis of schwannomatosis, a paradigm for the co-involvement of multiple tumour suppressor genes in tumorigenesis.

Authors:  Hildegard Kehrer-Sawatzki; Said Farschtschi; Victor-Felix Mautner; David N Cooper
Journal:  Hum Genet       Date:  2016-12-05       Impact factor: 4.132

Review 8.  Current Understanding of Neurofibromatosis Type 1, 2, and Schwannomatosis.

Authors:  Ryota Tamura
Journal:  Int J Mol Sci       Date:  2021-05-29       Impact factor: 5.923

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.